Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Emergent BioSolutions Inc.

Get SEC filing alerts via email and in your feed for Emergent BioSolutions Inc.

EBS

Emergent BioSolutions Inc.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global life sciences company specializing in developing and manufacturing medical countermeasures, vaccines, therapeutics, and diagnostics for public health threats like bioweapons, infectious diseases, and emergencies. Its core segments include government-focused biodefense products, commercial vaccines like NARCAN, and bioservices supporting drug development. The company leverages government contracts, proprietary technologies, and strategic partnerships to deliver lifesaving solutions worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Emergent BioSolutions Inc.

1
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports 30% Revenue Decline and 90% Drop in Net Income for Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Emergent BioSolutions Inc. Emergent BioSolutions Inc. Reports 29% Revenue Decline in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports 21% Revenue Decline in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports 45% Revenue Decline in Q2 2025, Net Loss Improves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports 26% Revenue Decline and Increased Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports $190.6 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Emergent BioSolutions Inc. Emergent BioSolutions Reports 9% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments